No Data
No Data
Verve Therapeutics Price Target Cut to $29.00/Share From $30.00 by Canaccord Genuity
Express News | HC Wainwright & Co. Reiterates Buy on Verve Therapeutics, Maintains $15 Price Target
Verve Therapeutics, Inc. (NASDAQ:VERV) Just Reported Earnings, And Analysts Cut Their Target Price
Express News | RBC Capital Maintains Outperform on Verve Therapeutics, Lowers Price Target to $20
Buy Rating Affirmed for Verve Therapeutics Amidst Clinical Progress and Strong Financials
Express News | Verve Therapeutics Inc : Canaccord Genuity Cuts Target Price to $29 From $30
No Data
DazzyJazzy : What is it going to be? 4.555 now… when is the bull?